The phase III study was evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM).

Doctors inspired by the results of a global trial, called STRONG-HF, are giving hope to around 100 patients and their families affected by heart failure in London. Those with the condition are ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Cognitive Decline Comes Sooner for People With Heart Failure Apr. 3, 2025 — There are over six million Americans with heart failure who are at greater risk of losing their cognitive abilities ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the ...

Another study, conducted in elderly patients (mean age 81 years), enrolled patients 62 years and older with NYHA class II or III heart failure, prior Q-wave myocardial infarction, and ejection ...

Without treatment, however, it increases the risk of cardiac arrest, heart failure, stroke, and other complications. Different conditions and factors can cause the heart rate to jump up or down.

Aims: Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on ...

“The Government needs to step in and wave the big stick.” Many areas along Northland’s east coast were impacted by the lack of telecommunications, including Huruiki near Helena Bay, the ...